A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RO7017773 in Healthy Participants

Inclusion criteria

• Healthy (absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, serology and urinalysis) as judged by the Investigator.
• Male and women of non-childbearing potential (WONCBP)

Exclusion criteria

• History of convulsions (other than benign febrile convulsions of childhood) including epilepsy, or personal history of significant cerebral trauma or central nervous system (CNS) infections (e.g., meningitis)
• History of clinically significant hypersensitivity or allergic reactions
• Abnormal blood pressure
• Abnormal pulse rate
• History or presence of clinically significant ECG abnormalities before study drug administration or cardiovascular disease
• Current or chronic history of liver disease, or known hepatic or biliary abnormalities
• Positive test for drugs of abuse or alcohol
• Evidence of human immunodeficiency virus (HIV) infection
• Presence of hepatitis B surface antigen (HBsAg) or positive HCV antibody test result at screening or within 3 months prior to starting study treatment
• Participants who regularly smoke more than 5 cigarettes daily or the equivalent and are unable or unwilling not to smoke during the in-house period